Wakuda K, Kenmotsu H, Sato Y, Nakamura A, et al. Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH BMC Cancer 2023;23:902.
PMID: 37749521